US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
JP2000505471A
(ja)
|
1996-02-28 |
2000-05-09 |
メルク エンド カンパニー インコーポレーテッド |
フィブリノーゲン受容体拮抗物質
|
JP2001002661A
(ja)
|
1999-06-22 |
2001-01-09 |
Ricoh Co Ltd |
ニトリル化合物及びその製造方法
|
US6465648B1
(en)
|
1999-06-22 |
2002-10-15 |
Ricoh Company, Ltd. |
Reaction product, process of producing same, electrophotographic photoconductor using same, electrophotographic apparatus having the photoconductor, and process cartridge for electrophotographic apparatus
|
NZ517828A
(en)
|
1999-09-17 |
2003-10-31 |
Millennium Pharm Inc |
Inhibitors having activity against mammalian factor Xa
|
US6632815B2
(en)
|
1999-09-17 |
2003-10-14 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
WO2001056989A2
(en)
|
2000-02-01 |
2001-08-09 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
JP2001335476A
(ja)
|
2000-05-29 |
2001-12-04 |
Shionogi & Co Ltd |
三環化合物の新規用途
|
US6599926B2
(en)
|
2000-06-23 |
2003-07-29 |
Bristol-Myers Squibb Company |
Heteroaryl-phenyl substituted factor Xa inhibitors
|
AU2001288617A1
(en)
|
2000-09-05 |
2002-03-22 |
Neogenesis Pharmaceuticals Inc. |
Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
|
US20020115106A1
(en)
|
2000-12-22 |
2002-08-22 |
Neogenesis Pharmaceuticals, Inc. |
Methods for forming combinatorial libraries using reductive amination
|
DE10104279A1
(de)
|
2001-01-31 |
2002-08-01 |
Heinz Langhals |
Kompetitive Prionen-Reagenzien und ihre Anwendung in Diagnostik und Therapie
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
EP1426046A4
(en)
|
2001-09-14 |
2005-11-02 |
Shionogi & Co |
NEW USE OF TRICYCLIC COMPOUNDS
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
CA2509042A1
(en)
|
2002-12-11 |
2004-06-24 |
Eli Lilly And Company |
Novel mch receptor antagonists
|
JP4695395B2
(ja)
|
2002-12-13 |
2011-06-08 |
ニューロジェン・コーポレーション |
疼痛治療用の併用療法
|
WO2004084824A2
(en)
|
2003-03-24 |
2004-10-07 |
Merck & Co., Inc. |
Biaryl substituted 6-membered heterocyles as sodium channel blockers
|
US7244763B2
(en)
|
2003-04-17 |
2007-07-17 |
Warner Lambert Company Llc |
Compounds that modulate PPAR activity and methods of preparation
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
GB0325956D0
(en)
|
2003-11-06 |
2003-12-10 |
Addex Pharmaceuticals Sa |
Novel compounds
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
JP2007527908A
(ja)
|
2004-03-08 |
2007-10-04 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
抗原虫薬としての新規ジカチオン性イミダゾ[1,2−a]ピリジン、及び5,6,7,8−テトラヒドロ−イミダゾ[1,2−a]ピリジン
|
WO2005095338A1
(ja)
|
2004-03-30 |
2005-10-13 |
Takeda Pharmaceutical Company Limited |
アルコキシフェニルプロパン酸誘導体
|
CA2566609C
(en)
|
2004-05-13 |
2012-06-26 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
US20060019967A1
(en)
|
2004-07-21 |
2006-01-26 |
Su-Ying Wu |
SARS CoV main protease inhibitors
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
US20080021069A1
(en)
|
2004-10-08 |
2008-01-24 |
Takeda Pharmaceutical Company Limited |
Receptor Function Regulating Agent
|
JP5785354B2
(ja)
|
2004-11-03 |
2015-09-30 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
インスリン関連障害の処置のためのgpr41およびその調節因子
|
US20080090865A1
(en)
|
2005-01-28 |
2008-04-17 |
Min Ge |
Antidiabetic Bicyclic Compounds
|
AU2006210954A1
(en)
|
2005-01-31 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
EP1845988A2
(en)
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines and imidazonaphthyridines
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
SI2161336T1
(sl)
|
2005-05-09 |
2013-11-29 |
Ono Pharmaceutical Co., Ltd. |
Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
|
GB0510141D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B3
|
US7465804B2
(en)
|
2005-05-20 |
2008-12-16 |
Amgen Inc. |
Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
|
BRPI0613361A2
(pt)
|
2005-07-01 |
2011-01-04 |
Medarex Inc |
anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
|
EP1916234B1
(en)
|
2005-07-29 |
2014-11-12 |
Takeda Pharmaceutical Company Limited |
Cyclopropanecarboxylic acid compound
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
CA2621949A1
(en)
|
2005-09-14 |
2007-03-22 |
Amgen Inc. |
Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
|
CA2625988A1
(en)
|
2005-10-19 |
2007-04-26 |
Merck & Co., Inc. |
Cetp inhibitors
|
WO2007049050A2
(en)
|
2005-10-27 |
2007-05-03 |
Heptahelix Ab |
Modulators of gpr40 for the treatment of diabetes
|
WO2007052466A1
(ja)
|
2005-11-04 |
2007-05-10 |
Eisai R & D Management Co., Ltd. |
Gpr40とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
|
US20100249175A1
(en)
|
2005-12-02 |
2010-09-30 |
Wilson W David |
Dicationic compounds which selectively recognize G-quadruplex DNA
|
HUE031972T2
(en)
|
2005-12-29 |
2017-08-28 |
Celtaxsys Inc |
Diamin derivatives as leukotriene A4 hydrolase inhibitors
|
US20090028793A1
(en)
|
2006-02-22 |
2009-01-29 |
Philogen Spa |
Vascular Tumor Markers
|
EP2001844A2
(en)
|
2006-03-14 |
2008-12-17 |
Amgen, Inc |
Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
|
DE102006012251A1
(de)
|
2006-03-15 |
2007-11-08 |
Grünenthal GmbH |
Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
|
SG170728A1
(en)
|
2006-03-23 |
2011-05-30 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
PT2402319T
(pt)
|
2006-03-31 |
2017-12-11 |
Novartis Ag |
Inibidores de dgat
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
EP1849781A1
(en)
|
2006-04-28 |
2007-10-31 |
Laboratorios del Dr. Esteve S.A. |
Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
|
MX2008013990A
(es)
|
2006-05-09 |
2009-01-29 |
Pfizer Prod Inc |
Derivados de cicloalquilamino acidos.
|
DE102006021878A1
(de)
|
2006-05-11 |
2007-11-15 |
Sanofi-Aventis |
Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102006021872B4
(de)
|
2006-05-11 |
2008-04-17 |
Sanofi-Aventis |
4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102006021874B4
(de)
|
2006-05-11 |
2008-03-27 |
Sanofi-Aventis |
4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
BRPI0711416A2
(pt)
|
2006-05-11 |
2011-11-01 |
Sanofi Aventis |
ácidos carboxìlicos substituìdos com 4,5-difenil pirimidinila, processo para a produção e uso dos mesmos como medicamentos
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
RU2444521C2
(ru)
|
2006-06-27 |
2012-03-10 |
Такеда Фармасьютикал Компани Лимитед |
Конденсированные циклические соединения
|
WO2008014236A1
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2064193A1
(en)
|
2006-09-07 |
2009-06-03 |
Amgen, Inc |
Heterocyclic gpr40 modulators
|
WO2008037266A1
(en)
|
2006-09-25 |
2008-04-03 |
Universite Libre De Bruxelles |
Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
|
US8338394B2
(en)
|
2006-10-12 |
2012-12-25 |
Case Western Reserve University |
Methods for treating metabolic diseases
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
US8039484B2
(en)
|
2006-10-31 |
2011-10-18 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
TW200838526A
(en)
|
2006-12-01 |
2008-10-01 |
Astellas Pharma Inc |
Carboxylic acid derivatives
|
WO2008065409A2
(en)
|
2006-12-01 |
2008-06-05 |
Betagenon Ab |
Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
|
WO2008067644A1
(en)
|
2006-12-04 |
2008-06-12 |
Boehringer Ingelheim International Gmbh |
Inhibitors of hiv replication
|
BRPI0720023A2
(pt)
|
2006-12-11 |
2018-09-04 |
Novartis Ag |
método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1
|
AU2007338792B2
(en)
|
2006-12-20 |
2012-05-31 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
ES2415863T3
(es)
|
2006-12-22 |
2013-07-29 |
Incyte Corporation |
Heterociclos sustituidos como inhibidores de Janus Quinasas
|
ES2548353T3
(es)
|
2006-12-28 |
2015-10-15 |
Abbvie Inc. |
Inhibidores de poli(ADP-ribosa)polimerasa
|
WO2008090327A1
(en)
|
2007-01-22 |
2008-07-31 |
Betagenon Ab |
New combination for use in the treatment of cancer
|
WO2008090356A1
(en)
|
2007-01-25 |
2008-07-31 |
Betagenon Ab |
Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
|
WO2008106202A1
(en)
|
2007-02-27 |
2008-09-04 |
Housey Gerard M |
Theramutein modulators
|
DK2152701T3
(en)
|
2007-03-12 |
2016-02-15 |
Ym Biosciences Australia Pty |
Phenylaminopyrimidinforbindelser and uses thereof
|
CA2683751C
(en)
|
2007-04-16 |
2013-01-08 |
Amgen Inc. |
Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
|
EP2151236A4
(en)
|
2007-04-26 |
2013-01-16 |
Japan Science & Tech Agency |
G PROTEIN COUPLED RECEPTOR AGONIST
|
US20090214529A9
(en)
|
2007-05-22 |
2009-08-27 |
Taigen Biotechnology Co., Ltd. |
Kinesin inhibitors
|
US20100203012A1
(en)
|
2007-05-30 |
2010-08-12 |
Aegera Therapeutics, Inc. |
Iap bir domain binding compounds
|
EP2002838A1
(de)
|
2007-06-13 |
2008-12-17 |
Bayer Schering Pharma AG |
Verwendung von Aryl/Hetarylamid-Derivaten als Modulatoren des EP2-Rezeptors
|
WO2008156656A2
(en)
|
2007-06-13 |
2008-12-24 |
State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Method for making biaryl compounds, compounds made by the method, and method for their use
|
US7968544B2
(en)
|
2007-06-29 |
2011-06-28 |
Gilead Sciences, Inc. |
Modulators of toll-like receptor 7
|
JP5312459B2
(ja)
|
2007-08-02 |
2013-10-09 |
ジリード バイオロジクス,インク. |
Loxおよびloxl2阻害剤ならびにこれらの使用
|
TW200911798A
(en)
|
2007-08-02 |
2009-03-16 |
Amgen Inc |
PI3 kinase modulators and methods of use
|
TWI461411B
(zh)
|
2007-08-17 |
2014-11-21 |
Du Pont |
製備5-鹵烷基-4,5-二氫異唑衍生物之方法
|
WO2009038204A1
(ja)
|
2007-09-17 |
2009-03-26 |
Pharma Frontier Co., Ltd. |
新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするgタンパク質共役型レセプター作動剤
|
WO2009039943A1
(de)
|
2007-09-21 |
2009-04-02 |
Sanofi-Aventis |
(carboxylalkylen-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
BRPI0817198A2
(pt)
|
2007-09-21 |
2015-03-17 |
Sanofi Aventis |
(ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
|
US8501955B2
(en)
|
2007-10-08 |
2013-08-06 |
Advinus Therapeutics Private Limited |
Acetamide derivatives as glucokinase activators, their process and medicinal application
|
BRPI0818253A2
(pt)
|
2007-10-10 |
2015-04-07 |
Amgen Inc |
Moduladores de gpr40 bifenil substituídos
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
EP2206707B1
(en)
|
2007-10-24 |
2014-07-23 |
Astellas Pharma Inc. |
Azolecarboxamide compound or salt thereof
|
BRPI0818687A2
(pt)
|
2007-10-26 |
2017-05-02 |
Japan Tobacco Inc |
composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
|
AU2008319418B2
(en)
|
2007-10-29 |
2013-08-15 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2011515341A
(ja)
|
2008-03-06 |
2011-05-19 |
アムジエン・インコーポレーテツド |
代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
|
WO2009112445A1
(en)
|
2008-03-10 |
2009-09-17 |
Novartis Ag |
Method of increasing cellular phosphatidyl choline by dgat1 inhibition
|
PE20110308A1
(es)
|
2008-07-08 |
2011-06-10 |
Incyte Corp |
1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
|
EP3103875A1
(en)
|
2008-07-21 |
2016-12-14 |
Apogenix AG |
Tnfsf single chain molecules
|
CN102137836B
(zh)
|
2008-07-28 |
2015-08-26 |
赛丹思科大学 |
用于治疗代谢疾病的化合物
|
CA2732437C
(en)
|
2008-08-01 |
2017-11-21 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
EP2350006A1
(en)
|
2008-10-01 |
2011-08-03 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
US8748462B2
(en)
|
2008-10-15 |
2014-06-10 |
Amgen Inc. |
Spirocyclic GPR40 modulators
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
JP2012510979A
(ja)
|
2008-12-08 |
2012-05-17 |
ユーロスクリーン・ソシエテ・アノニム |
化合物、薬学的組成物および代謝障害の治療において使用するための方法
|
ES2623794T3
(es)
|
2008-12-09 |
2017-07-12 |
Gilead Sciences, Inc. |
Intermedios para la preparación de moduladores de receptores tipo toll
|
RU2505540C2
(ru)
|
2008-12-23 |
2014-01-27 |
Эббви Инк. |
Антивирусные соединения
|
SG172800A1
(en)
|
2009-01-19 |
2011-08-29 |
Daiichi Sankyo Co Ltd |
Heteroatom-containing cyclic compound
|
US20110312967A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
WO2010085522A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Pentafluorosulpholane-containing antidiabetic compounds
|
US20110312995A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
WO2010091176A1
(en)
|
2009-02-05 |
2010-08-12 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
EP2393359A4
(en)
|
2009-02-09 |
2012-10-03 |
Enanta Pharm Inc |
COMPOUND DIBENZIMIDAZOLE DERIVATIVES
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
BRPI1007836A2
(pt)
|
2009-02-27 |
2015-09-01 |
Enanta Phamaceuticals Inc |
Inibidores do vírus c da hepatite
|
JP5735482B2
(ja)
|
2009-03-27 |
2015-06-17 |
プレシディオ ファーマシューティカルズ インコーポレイテッド |
縮合環のc型肝炎阻害剤
|
JPWO2010123016A1
(ja)
|
2009-04-22 |
2012-10-25 |
アステラス製薬株式会社 |
カルボン酸化合物
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
TWI629981B
(zh)
|
2009-05-13 |
2018-07-21 |
基利法瑪席特有限責任公司 |
抗病毒化合物
|
JP5657578B2
(ja)
|
2009-06-09 |
2015-01-21 |
武田薬品工業株式会社 |
新規な縮合環化合物およびその用途
|
SG10201702522UA
(en)
|
2009-06-11 |
2017-05-30 |
Abbvie Bahamas Ltd |
Anti-viral compounds to treat hcv infection
|
TWI625121B
(zh)
|
2009-07-13 |
2018-06-01 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
AU2010284241B2
(en)
|
2009-08-18 |
2016-11-10 |
Array Biopharma, Inc. |
Substituted benzoazepines as Toll-like receptor modulators
|
DK2467377T3
(en)
|
2009-08-18 |
2017-04-03 |
Ventirx Pharmaceuticals Inc |
SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
|
GB0914856D0
(en)
|
2009-08-25 |
2009-09-30 |
Ark Therapeutics Ltd |
Compounds
|
WO2011031934A1
(en)
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
NZ598384A
(en)
|
2009-09-14 |
2014-04-30 |
Gilead Sciences Inc |
Modulators of toll-like receptors
|
EP2486005B1
(en)
|
2009-10-06 |
2014-06-18 |
Bristol-Myers Squibb Company |
Pyrrolidine gpr40 modulators
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
NO2491035T3
(es)
|
2009-10-22 |
2018-01-27 |
|
|
EP2495238A4
(en)
|
2009-10-30 |
2013-04-24 |
Mochida Pharm Co Ltd |
NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
JP2013512246A
(ja)
|
2009-11-25 |
2013-04-11 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
CN102812003B
(zh)
|
2009-12-18 |
2015-01-21 |
欧洲筛选有限公司 |
吡咯烷羧酸衍生物、药物组合物以及在代谢紊乱中作为g-蛋白偶联受体43(gpr43)激动剂使用的方法
|
WO2011076732A1
(en)
|
2009-12-21 |
2011-06-30 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
|
WO2011076734A1
(en)
|
2009-12-21 |
2011-06-30 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
|
EP2518060A4
(en)
|
2009-12-25 |
2014-01-08 |
Mochida Pharm Co Ltd |
NEW 3-HYDROXY-5-ARYLISOTHIAZOL DERIVATIVE
|
WO2011080755A1
(en)
|
2009-12-29 |
2011-07-07 |
Advinus Therapeutics Private Limited |
Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
WO2011092284A1
(en)
|
2010-01-29 |
2011-08-04 |
Euroscreen S.A. |
Novel amino acid derivatives and their use as gpr43 receptor modulators
|
SG183174A1
(en)
|
2010-02-04 |
2012-09-27 |
Gilead Biologics Inc |
Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
EP2550262A1
(en)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
JP2013522377A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
AU2011235301B2
(en)
|
2010-03-30 |
2013-07-18 |
Novartis Ag |
Uses of DGAT1 inhibitors
|
US8686048B2
(en)
|
2010-05-06 |
2014-04-01 |
Rhizen Pharmaceuticals Sa |
Immunomodulator and anti-inflammatory compounds
|
SG185414A1
(en)
|
2010-05-12 |
2012-12-28 |
Univ Vanderbilt |
Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
CN103179976A
(zh)
|
2010-05-13 |
2013-06-26 |
印第安纳大学研究及科技有限公司 |
呈现g蛋白偶联受体活性的胰高血糖素超家族肽
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
MX2012013622A
(es)
|
2010-05-31 |
2013-02-01 |
Ono Pharmaceutical Co |
Derivado de purinona.
|
WO2011151436A2
(en)
|
2010-06-04 |
2011-12-08 |
Euroscreen S.A. |
Novel compounds, method for use them and pharmaceutical composition containing them
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
JP2012036168A
(ja)
|
2010-07-15 |
2012-02-23 |
Daiichi Sankyo Co Ltd |
ヘテロ原子を有する環状化合物を含有する医薬組成物
|
WO2012011124A1
(en)
|
2010-07-20 |
2012-01-26 |
Council Of Scientific & Industrial Research |
Ordered mesoporous titanosilicate and the process for the preparation thereof
|
WO2012012627A1
(en)
|
2010-07-22 |
2012-01-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of preventing or treating viral infection
|
NZ606880A
(en)
|
2010-08-27 |
2015-01-30 |
Gilead Biologics Inc |
Antibodies to matrix metalloproteinase 9
|
JP5850503B2
(ja)
|
2010-09-14 |
2016-02-03 |
北海道公立大学法人 札幌医科大学 |
筋ジストロフィーを処置するための組成物
|
WO2012050918A2
(en)
|
2010-09-29 |
2012-04-19 |
Presidio Pharmaceutical, Inc. |
Tricyclic fused ring inhibitors of hepatitis c
|
US20120219615A1
(en)
|
2010-10-01 |
2012-08-30 |
The Trustees Of The University Of Pennsylvania |
Therapeutic Use of a TLR Agonist and Combination Therapy
|
RU2587061C2
(ru)
|
2010-10-01 |
2016-06-10 |
Вентиркс Фармасьютикалз, Инк. |
Способы лечения аллергических заболеваний
|
JP5809157B2
(ja)
|
2010-10-08 |
2015-11-10 |
持田製薬株式会社 |
環状アミド誘導体
|
EP2640701B1
(en)
|
2010-11-15 |
2017-07-05 |
Bayer Intellectual Property GmbH |
Cyanoenamines and their use as fungicides
|
KR20180026563A
(ko)
|
2010-11-17 |
2018-03-12 |
길리애드 파마셋 엘엘씨 |
항바이러스 화합물
|
US20130310379A1
(en)
|
2010-11-19 |
2013-11-21 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
DK2646425T3
(en)
|
2010-12-01 |
2015-08-24 |
Boehringer Ingelheim Int |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome.
|
WO2012078802A1
(en)
|
2010-12-08 |
2012-06-14 |
Takeda Pharmaceutical Company Limited |
PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES
|
EP3305798A1
(en)
|
2010-12-09 |
2018-04-11 |
The Trustees of The University of Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
AR084217A1
(es)
|
2010-12-10 |
2013-05-02 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
WO2012083059A1
(en)
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
US20150031884A1
(en)
|
2010-12-15 |
2015-01-29 |
Abbvie Inc. |
Anti-viral compounds
|
EP2651920A4
(en)
|
2010-12-15 |
2014-12-17 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
EP2651923A4
(en)
|
2010-12-15 |
2014-06-18 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
EP2651926A4
(en)
|
2010-12-15 |
2014-07-09 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
WO2012088438A1
(en)
|
2010-12-22 |
2012-06-28 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
PL2663550T4
(pl)
|
2011-01-12 |
2017-07-31 |
Ventirx Pharmaceuticals, Inc. |
Podstawione benzoazepiny jako modulatory receptora toll-podobnego
|
PL2663555T4
(pl)
|
2011-01-12 |
2017-08-31 |
Ventirx Pharmaceuticals, Inc. |
Podstawione benzoazepiny jako modulatory receptora toll-podobnego
|
AU2012208693B2
(en)
|
2011-01-19 |
2015-02-26 |
Galapagos Nv |
Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
|
CA2825306C
(en)
|
2011-01-25 |
2019-02-26 |
The Regents Of The University Of Michigan |
Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
|
EP2672820B1
(en)
|
2011-02-07 |
2019-04-17 |
The Washington University |
Mannoside compounds and methods of use thereof
|
EA028659B1
(ru)
|
2011-02-12 |
2017-12-29 |
Глоубиммьюн, Инк. |
Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
|
EP2675774A1
(en)
|
2011-02-17 |
2013-12-25 |
Takeda Pharmaceutical Company Limited |
Production method of optically active dihydrobenzofuran derivative
|
WO2012129562A2
(en)
|
2011-03-24 |
2012-09-27 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
JP6054368B2
(ja)
|
2011-04-08 |
2016-12-27 |
カルダン セラピューティクス リミテッドCaldan Therapeutics Limited |
代謝性疾患治療用o−フルオロ置換化合物またはその塩
|
RS60191B1
(sr)
|
2011-04-08 |
2020-06-30 |
Janssen Sciences Ireland Unlimited Co |
Derivati pirimidina za tretman virusnih infekcija
|
AR085990A1
(es)
|
2011-04-27 |
2013-11-13 |
Mochida Pharm Co Ltd |
Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
|
WO2012154608A1
(en)
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
JP5659189B2
(ja)
|
2011-05-13 |
2015-01-28 |
富士フイルム株式会社 |
非共鳴2光子吸収材料、非共鳴2光子吸収記録材料、記録媒体、記録再生方法及び非共鳴2光子吸収化合物
|
SI2709989T1
(en)
|
2011-05-18 |
2018-04-30 |
Janssen Sciences Ireland Uc |
Quinazoline derivatives for the treatment of viral infections and other diseases
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
WO2013009259A1
(en)
|
2011-07-14 |
2013-01-17 |
Biochromix Pharma Ab |
Novel compounds and their use in therapy
|
TWI537262B
(zh)
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
US9550835B2
(en)
|
2011-08-23 |
2017-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DDR1 antibody having anti-tumor activity
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
WO2013052699A2
(en)
|
2011-10-04 |
2013-04-11 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
HUE031094T2
(en)
|
2011-11-29 |
2017-07-28 |
Ono Pharmaceutical Co |
Purinone derivative hydrochloride
|
EP2794565B1
(en)
|
2011-12-21 |
2017-07-26 |
Novira Therapeutics Inc. |
Hepatitis b antiviral agents
|
WO2013102626A1
(en)
|
2012-01-04 |
2013-07-11 |
Sanofi |
3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament
|
JP6122871B2
(ja)
|
2012-01-12 |
2017-04-26 |
ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. |
多環式化合物誘導体、それらの製造方法および医薬用途
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2013209958B2
(en)
|
2012-01-16 |
2017-09-07 |
Vertex Pharmaceuticals Incorporated |
Pyran-spirocyclic piperidine amides as modulators of ion channels
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(en)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
|
JP6283320B2
(ja)
|
2012-02-08 |
2018-02-21 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
|
JP6095580B2
(ja)
|
2012-02-13 |
2017-03-15 |
武田薬品工業株式会社 |
芳香環化合物
|
US9181186B2
(en)
|
2012-02-13 |
2015-11-10 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
NZ631569A
(en)
|
2012-02-28 |
2016-10-28 |
Piramal Entpr Ltd |
Phenyl alkanoic acid derivatives as gpr agonists
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
RU2014142598A
(ru)
|
2012-03-31 |
2016-05-27 |
Ф. Хоффманн-Ля Рош Аг |
Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
US8975398B2
(en)
|
2012-05-11 |
2015-03-10 |
Abbvie Inc. |
NAMPT inhibitors
|
EP2852585A1
(en)
|
2012-05-11 |
2015-04-01 |
AbbVie Inc. |
Nampt inhibitors
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
ES2656087T3
(es)
|
2012-06-08 |
2018-02-23 |
Gilead Sciences, Inc. |
Inhibidores macrocíclicos de virus Flaviviridae
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
JP6209601B2
(ja)
|
2012-06-08 |
2017-10-04 |
ギリアード サイエンシーズ, インコーポレイテッド |
フラビウイルス科ウイルスの大環状阻害剤
|
US20140024708A1
(en)
|
2012-07-17 |
2014-01-23 |
Banavara L. Mylari |
Ursolic acid salts for treating diabetes and obesity
|
JP2015127299A
(ja)
|
2012-07-19 |
2015-07-09 |
武田薬品工業株式会社 |
固形製剤
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
BR112015002524B1
(pt)
|
2012-08-10 |
2021-11-03 |
Janssen Sciences Ireland Uc |
Derivados de alquilpirimidina, composição farmacêutica que os compreende e uso dos mesmos
|
WO2014035827A1
(en)
|
2012-08-27 |
2014-03-06 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
DK2890683T3
(en)
|
2012-08-28 |
2017-01-30 |
Janssen Sciences Ireland Uc |
MERGED BICYCLIC SULFAMOYL DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
NZ704752A
(en)
|
2012-08-28 |
2018-06-29 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
CA2881322A1
(en)
|
2012-09-10 |
2014-03-13 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
US20140073631A1
(en)
|
2012-09-12 |
2014-03-13 |
Vymed Corporation |
Antiviral and antimicrobial compounds
|
WO2014047624A1
(en)
|
2012-09-24 |
2014-03-27 |
Gilead Sciences, Inc. |
Anti-ddr1 antibodies
|
MD20150043A2
(ro)
|
2012-10-02 |
2015-08-31 |
Epitherapeutics Aps |
Inhibitori ai histon-demetilazelor
|
TR201807076T4
(tr)
|
2012-10-10 |
2018-06-21 |
Janssen Sciences Ireland Uc |
Viral enfeksiyonların ve diğer hastalıkların tedavisine yönelik pirolo[3,2-d]pirimidin derivatları.
|
US10034939B2
(en)
|
2012-10-26 |
2018-07-31 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
US20140128333A1
(en)
|
2012-11-02 |
2014-05-08 |
Maqui New Life S.A. |
Compounds, Compositions, and Methods for Decreasing Intestinal Glucose Uptake and Inducing Incretin Release
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
KR101268466B1
(ko)
|
2012-11-12 |
2013-06-04 |
유병수 |
사축형 윈드 터빈
|
MX358499B
(es)
|
2012-11-16 |
2018-08-23 |
Bristol Myers Squibb Co |
Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
|
JP6322202B2
(ja)
|
2012-11-16 |
2018-05-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
ピロリジンgpr40修飾因子
|
EP2925726B1
(en)
|
2012-11-16 |
2016-10-26 |
Bristol-Myers Squibb Company |
Dihydropyrazole gpr40 modulators
|
EP2925729B1
(en)
|
2012-11-16 |
2017-10-18 |
Janssen Sciences Ireland UC |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
CN104884452A
(zh)
|
2012-11-20 |
2015-09-02 |
沃泰克斯药物股份有限公司 |
用作吲哚胺2,3-二氧化酶的抑制剂的化合物
|
EA201500574A1
(ru)
|
2012-11-28 |
2015-11-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Новые инданилоксидигидробензофуранилуксусные кислоты
|
WO2014089364A1
(en)
|
2012-12-06 |
2014-06-12 |
Quanticel Pharmaceuticals, Inc |
Histone demethylase inhibitors
|
US20140163025A1
(en)
|
2012-12-07 |
2014-06-12 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
DK2934145T3
(en)
|
2012-12-19 |
2018-02-05 |
Celgene Quanticel Res Inc |
HISTONDEMETHYLASE INHIBITORS
|
ES2685568T3
(es)
|
2012-12-21 |
2018-10-10 |
Gilead Calistoga Llc |
Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
|
PT2941426T
(pt)
|
2012-12-21 |
2018-07-18 |
Gilead Calistoga Llc |
Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase
|
CA2895808A1
(en)
|
2012-12-21 |
2014-06-26 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
WO2014122067A1
(en)
|
2013-02-06 |
2014-08-14 |
Boehringer Ingelheim International Gmbh |
New indanyloxydihydrobenzofuranylacetic acids
|
KR102300861B1
(ko)
|
2013-02-21 |
2021-09-10 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
|
BR112015019836A2
(pt)
|
2013-02-22 |
2017-07-18 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso de um composto
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
US9642843B2
(en)
|
2013-02-27 |
2017-05-09 |
The Regents Of The University Of Michigan |
Pharmaceutical compounds and use of same in cancer and tauopathies
|
US10125094B2
(en)
|
2013-02-28 |
2018-11-13 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
|
AU2014221489B2
(en)
|
2013-02-28 |
2018-03-08 |
Tiumbio Co., Ltd. |
Tricyclic compound and use thereof
|
WO2014164708A1
(en)
|
2013-03-12 |
2014-10-09 |
Quanticel Pharmaceuticals, Inc. |
Histone dementhylase inhibitors
|
WO2014165128A2
(en)
|
2013-03-12 |
2014-10-09 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
MX2015011898A
(es)
|
2013-03-13 |
2016-05-05 |
Genentech Inc |
Compuestos de pirazolo y usos de los mismos.
|
JP6276378B2
(ja)
|
2013-03-14 |
2018-02-07 |
セルジーン クオンティセル リサーチ,インク. |
ヒストンデメチラーゼ阻害剤
|
US9763905B2
(en)
|
2013-03-15 |
2017-09-19 |
The Children's Medical Center Corporation |
Therapeutic target for the treatment of cancers and related therapies and methods
|
WO2014151106A1
(en)
|
2013-03-15 |
2014-09-25 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
ES2640063T3
(es)
|
2013-04-03 |
2017-10-31 |
Janssen Sciences Ireland Uc |
Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
WO2014170842A2
(en)
|
2013-04-17 |
2014-10-23 |
Piramal Enterprises Limited |
Substituted alkyl carboxylic acid derivatives as gpr agonists
|
KR101569522B1
(ko)
|
2013-04-18 |
2015-11-17 |
현대약품 주식회사 |
신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
EP2997032B1
(en)
|
2013-05-17 |
2018-07-25 |
F.Hoffmann-La Roche Ag |
6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
MX366787B
(es)
|
2013-05-17 |
2019-07-23 |
Janssen Sciences Ireland Uc |
Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b.
|
CN104870429B
(zh)
|
2013-05-22 |
2017-05-03 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
SI3008053T1
(en)
|
2013-06-14 |
2018-06-29 |
Gilead Calistoga Llc |
PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
|
CN104507921B
(zh)
|
2013-07-02 |
2017-02-22 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
US10478445B2
(en)
|
2013-07-03 |
2019-11-19 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
JP6730183B2
(ja)
|
2013-07-12 |
2020-07-29 |
ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー |
シストバクトアミド(Cystobactamides)
|
SG11201600522UA
(en)
|
2013-07-25 |
2016-02-26 |
Janssen Sciences Ireland Uc |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
CN105143181B
(zh)
|
2013-07-26 |
2017-12-26 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
ES2822285T3
(es)
|
2013-07-30 |
2021-04-30 |
Kronos Bio Inc |
Polimorfo de inhibidores de SYK
|
ES2672992T3
(es)
|
2013-08-09 |
2018-06-19 |
Takeda Pharmaceutical Company Limited |
Compuesto aromático
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
CN105473595A
(zh)
|
2013-08-23 |
2016-04-06 |
福建海西新药创制有限公司 |
治疗糖尿病的羧酸化合物
|
US9884865B2
(en)
|
2013-08-26 |
2018-02-06 |
Purdue Pharma L.P. |
Azaspiro[4.5] decane derivatives and use thereof
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
WO2015032328A1
(zh)
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
ES2642074T3
(es)
|
2013-09-04 |
2017-11-15 |
Bristol-Myers Squibb Company |
Compuestos útiles como inmunomoduladores
|
CA2922607C
(en)
|
2013-09-06 |
2022-08-30 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole derivatives as immunomodulators
|
CA2923090C
(en)
|
2013-09-11 |
2018-08-21 |
Poxel |
Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
|
EP3049396B1
(en)
|
2013-09-26 |
2017-11-15 |
Boehringer Ingelheim International GmbH |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US9567299B2
(en)
|
2013-10-23 |
2017-02-14 |
Janssen Sciences Ireland Uc |
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
CN104592211B
(zh)
|
2013-10-31 |
2018-10-16 |
广东东阳光药业有限公司 |
联苯类化合物及其用途
|
CN105722841A
(zh)
|
2013-11-14 |
2016-06-29 |
卡迪拉保健有限公司 |
新型杂环化合物
|
ES2777248T3
(es)
|
2013-11-14 |
2020-08-04 |
Novira Therapeutics Inc |
Derivados de azepano y métodos de tratar infecciones por hepatitis B
|
ES2747973T3
(es)
|
2013-11-15 |
2020-03-12 |
Merck Sharp & Dohme |
Compuestos tricíclicos antidiabéticos
|
US10584115B2
(en)
|
2013-11-21 |
2020-03-10 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine BMI-1 inhibitors
|
AU2014356460B2
(en)
|
2013-11-27 |
2020-01-16 |
Epics Therapeutics |
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
|
WO2015078802A1
(en)
|
2013-11-28 |
2015-06-04 |
Boehringer Ingelheim International Gmbh |
New indanyloxyphenylcyclopropanecarboxylic acids
|
US9957219B2
(en)
|
2013-12-04 |
2018-05-01 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2015085238A1
(en)
|
2013-12-05 |
2015-06-11 |
The Regents Of The University Of California, A California Corporation |
Inhibitors of lpxc
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
UY35898A
(es)
|
2013-12-23 |
2015-07-31 |
Gilead Sciences Inc |
?compuestos inhibidores de syk y composiciones que los comprenden?.
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
BR112016012469A2
(pt)
|
2014-01-10 |
2017-08-08 |
Lilly Co Eli |
Isopropil triazolo piridina, seus usos, seu processo de preparação e seus intermediários, composição farmacêutica
|
MX2016008910A
(es)
|
2014-01-10 |
2016-10-04 |
Lilly Co Eli |
Compuestos de fenil-triazolo-piridina.
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
EA201691261A1
(ru)
|
2014-01-30 |
2016-11-30 |
Ф. Хоффманн-Ля Рош Аг |
Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
|
AP2016009257A0
(en)
|
2014-02-06 |
2016-06-30 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
EP3102198B1
(en)
|
2014-02-06 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
EA030115B9
(ru)
|
2014-03-07 |
2018-09-28 |
Ф. Хоффманн-Ля Рош Аг |
Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
|
EP3119763A1
(en)
|
2014-03-18 |
2017-01-25 |
Iteos Therapeutics |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
LT3125883T
(lt)
|
2014-04-04 |
2020-10-26 |
Iomet Pharma Ltd. |
Indolo dariniai, skirti panaudoti medicinoje
|
RU2752275C2
(ru)
|
2014-04-10 |
2021-07-26 |
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) |
Способ и композиции для клеточной иммунотерапии
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
BR112016025188A2
(pt)
|
2014-05-07 |
2017-08-15 |
Bristol Myers Squibb Co |
moduladores de pirrolidina gpr40 para o tratamento de doenças tal como diabetes
|
TWI659951B
(zh)
|
2014-05-07 |
2019-05-21 |
美商必治妥美雅史谷比公司 |
吡咯啶gpr40調節劑
|
US10301260B2
(en)
|
2014-05-07 |
2019-05-28 |
Bristol-Myers Squibb Company |
Pyrrolidine GPR40 modulators
|
JP6568106B2
(ja)
|
2014-05-13 |
2019-08-28 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎ウイルス感染症の治療及び予防のための新規ジヒドロキノリジノン類
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015188085A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
JP6678599B2
(ja)
|
2014-06-13 |
2020-04-08 |
ユニバーシティー オブ ロチェスター |
小分子排出ポンプ阻害剤
|
GB201411239D0
(en)
|
2014-06-25 |
2014-08-06 |
Takeda Pharmaceutical |
Novel compounds
|
GB201411236D0
(en)
|
2014-06-25 |
2014-08-06 |
Takeda Pharmaceutical |
Novel compounds
|
TW201613878A
(en)
|
2014-07-09 |
2016-04-16 |
Janssen Pharmaceutica Nv |
Pyrazine GPR40 agonists for the treatment of type II diabetes
|
WO2016012470A1
(en)
|
2014-07-25 |
2016-01-28 |
F. Hoffmann-La Roche Ag |
New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
|
US10011572B2
(en)
|
2014-07-29 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
WO2016022446A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10968193B2
(en)
|
2014-08-08 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
BR112017002970B1
(pt)
|
2014-08-14 |
2023-04-11 |
F. Hoffmann-La Roche Ag |
Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
SG11201701182VA
(en)
|
2014-08-27 |
2017-03-30 |
Gilead Sciences Inc |
Compounds and methods for inhibiting histone demethylases
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
CN106999536B
(zh)
|
2014-09-11 |
2020-11-27 |
百时美施贵宝公司 |
Pd-1/pd-l1及cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂
|
UY35733A
(es)
|
2014-09-12 |
2016-04-01 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c.
|
WO2016041511A1
(en)
|
2014-09-19 |
2016-03-24 |
Yen-Ta Lu |
Benzo-heterocyclic compounds and their applications
|
SG11201701724VA
(en)
|
2014-09-26 |
2017-04-27 |
Gilead Sciences Inc |
Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
|
WO2016057924A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
US10059689B2
(en)
|
2014-10-14 |
2018-08-28 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
CN111423408A
(zh)
|
2014-10-17 |
2020-07-17 |
现代药品株式会社 |
代谢性疾病的预防或治疗用复合制剂
|
SG11201703188QA
(en)
*
|
2014-10-24 |
2017-05-30 |
Bristol Myers Squibb Co |
Indole carboxamides compounds useful as kinase inhibitors
|
KR101857146B1
(ko)
|
2014-10-28 |
2018-05-11 |
삼성에스디아이 주식회사 |
유기 광전자 소자 및 표시 장치
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
AU2015341913B2
(en)
|
2014-11-03 |
2020-07-16 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN107206025A
(zh)
|
2014-12-03 |
2017-09-26 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的方法和组合物
|
WO2016090300A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
JP6821568B2
(ja)
|
2014-12-15 |
2021-01-27 |
ベリカム ファーマシューティカルズ, インコーポレイテッド |
治療用細胞のコントロールされた排除方法
|
AR103222A1
(es)
|
2014-12-23 |
2017-04-26 |
Hoffmann La Roche |
Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
JP6506845B2
(ja)
|
2014-12-30 |
2019-04-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
CN107109497A
(zh)
|
2014-12-31 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
|
WO2016110821A1
(en)
|
2015-01-08 |
2016-07-14 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
MA41338B1
(fr)
|
2015-01-16 |
2019-07-31 |
Hoffmann La Roche |
Composés de pyrazine pour le traitement de maladies infectieuses
|
CN107208102B
(zh)
|
2015-01-27 |
2021-07-06 |
豪夫迈·罗氏有限公司 |
重组hbv cccdna、其产生方法及其用途
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP2018508569A
(ja)
|
2015-02-06 |
2018-03-29 |
ユニティ バイオテクノロジー インコーポレイテッド |
老化関連状態の治療における化合物および使用
|
CN107207505B
(zh)
|
2015-02-11 |
2018-12-14 |
豪夫迈·罗氏有限公司 |
治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
CN107405336A
(zh)
|
2015-03-10 |
2017-11-28 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的1,3,4‑噁二唑和噻二唑化合物
|
SG11201706901TA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
Therapeutic cyclic compounds as immunomodulators
|
CN107427477B
(zh)
|
2015-03-10 |
2021-11-26 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
|
MX2017011611A
(es)
|
2015-03-10 |
2018-03-23 |
Aurigene Discovery Tech Ltd |
Compuestos de tiadiazol y 1,3,4-oxadiazol 3-sustituidos como inmunomoduladores.
|
BR112017019304A2
(pt)
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
CN104876912B
(zh)
|
2015-04-08 |
2017-07-21 |
苏州云轩医药科技有限公司 |
Wnt信号通路抑制剂及其应用
|
ES2761824T3
(es)
|
2015-05-15 |
2020-05-21 |
Gilead Sciences Inc |
Compuestos de carboximidamida de benzimidazol y imidazopiridina que tienen actividad como inhibidores de indoleamina 2,3-dioxigenasa
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
AR104020A1
(es)
|
2015-06-04 |
2017-06-21 |
Kura Oncology Inc |
Métodos y composiciones para inhibir la interacción de menina con proteínas mill
|
CN107709336B
(zh)
|
2015-06-12 |
2021-06-22 |
杭州英创医药科技有限公司 |
作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
|
US20180230166A1
(en)
|
2015-07-13 |
2018-08-16 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
JP6816107B2
(ja)
|
2015-08-07 |
2021-01-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
|
WO2017027310A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
US9920040B2
(en)
|
2015-08-12 |
2018-03-20 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
WO2017031392A1
(en)
|
2015-08-20 |
2017-02-23 |
University Of Florida Research Foundation, Incorporated |
Lipid compounds for treatment of obesity, hypertension and metabolic syndrome
|
WO2017042121A1
(en)
|
2015-09-09 |
2017-03-16 |
Boehringer Ingelheim International Gmbh |
[{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
|
WO2017049166A1
(en)
|
2015-09-17 |
2017-03-23 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
ES2928164T3
(es)
|
2015-10-19 |
2022-11-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
CA3004083A1
(en)
|
2015-11-04 |
2017-05-11 |
Incyte Corporation |
Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
|
CA3005727A1
(en)
|
2015-11-19 |
2017-05-26 |
Incyte Corporation |
Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
|
CN114404595A
(zh)
|
2015-12-07 |
2022-04-29 |
国立大学法人京都大学 |
Pd-1信号抑制剂的并用疗法
|
WO2017106634A1
(en)
|
2015-12-17 |
2017-06-22 |
Incyte Corporation |
N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
|
PE20230731A1
(es)
|
2015-12-22 |
2023-05-03 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
CN110072864B
(zh)
|
2015-12-24 |
2022-05-27 |
基因泰克公司 |
Tdo2抑制剂
|
EP3190103A1
(en)
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
WO2017143220A1
(en)
|
2016-02-17 |
2017-08-24 |
Children's Medical Center Corporation |
Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9798514B2
(en)
|
2016-03-09 |
2017-10-24 |
Spotify Ab |
System and method for color beat display in a media content environment
|
US20190127314A1
(en)
|
2016-03-23 |
2019-05-02 |
Symrise Ag |
Homovanillic acid ester for reducing or inhibiting fatty acid absorption in the small intestine
|
WO2017172505A1
(en)
|
2016-03-29 |
2017-10-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2017180571A1
(en)
|
2016-04-11 |
2017-10-19 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
|
US10195178B2
(en)
|
2016-04-11 |
2019-02-05 |
Janssen Pharmaceutica Nv |
GPR40 agonists in anti-diabetic drug combinations
|
WO2017180769A1
(en)
|
2016-04-13 |
2017-10-19 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
CN107417564A
(zh)
|
2016-05-23 |
2017-12-01 |
中国医学科学院药物研究所 |
苯醚类衍生物、及其制法和药物组合物与用途
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
ES2905980T3
(es)
|
2016-05-26 |
2022-04-12 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
BR112018073920A2
(pt)
|
2016-05-26 |
2019-02-26 |
Merck Patent Gmbh |
inibidores de pd-1/pd-l1 para tratamento de câncer".
|
PE20190731A1
(es)
|
2016-06-20 |
2019-05-23 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
CN109803651B
(zh)
*
|
2016-06-27 |
2022-05-31 |
凯莫森特里克斯股份有限公司 |
免疫调节剂化合物
|
US10590105B2
(en)
|
2016-07-08 |
2020-03-17 |
Bristol-Meyers Squibb Company |
1,3-dihydroxy-phenyl derivatives useful as immunomodulators
|
CN109195602B
(zh)
|
2016-08-03 |
2022-01-07 |
上海齐鲁制药研究中心有限公司 |
用作免疫调节剂的对称或半对称化合物
|
EP3281937A1
(en)
|
2016-08-09 |
2018-02-14 |
Dompé farmaceutici S.p.A. |
Sulfonamides as gpr40- and gpr120-agonists
|
US10563620B2
(en)
|
2016-08-12 |
2020-02-18 |
Rolls-Royce North American Technologies Inc. |
Expandable exhaust cone
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
US10734026B2
(en)
|
2016-09-01 |
2020-08-04 |
Facebook, Inc. |
Systems and methods for dynamically providing video content based on declarative instructions
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
US20180065917A1
(en)
*
|
2016-09-02 |
2018-03-08 |
Polaris Pharmaceuticals, Inc. |
Immune checkpoint inhibitors, compositions and methods thereof
|
WO2018051255A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
WO2018051254A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
WO2018053302A1
(en)
|
2016-09-19 |
2018-03-22 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
|
WO2018081047A1
(en)
|
2016-10-25 |
2018-05-03 |
Janssen Pharmaceutica Nv |
Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
|
CN110088089B
(zh)
|
2016-10-25 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
|
US10125101B2
(en)
*
|
2016-11-28 |
2018-11-13 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
ES2891528T3
(es)
|
2016-12-20 |
2022-01-28 |
Bristol Myers Squibb Co |
Compuestos útiles como inmunomoduladores
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC SPIROCHROMAN COMPOUNDS
|
WO2018118664A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
|
BR112019012957A2
(pt)
|
2016-12-22 |
2019-11-26 |
Incyte Corp |
derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
MY197635A
(en)
|
2016-12-22 |
2023-06-29 |
Incyte Corp |
Benzooxazole derivatives as immunomodulators
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
CN108250159B
(zh)
|
2016-12-29 |
2023-07-11 |
深圳微芯生物科技股份有限公司 |
脲类化合物、其制备方法及其应用
|
CN110214135B
(zh)
|
2017-01-26 |
2023-02-21 |
勃林格殷格翰国际有限公司 |
茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途
|
JP7050792B2
(ja)
|
2017-01-26 |
2022-04-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
CN110198928B
(zh)
|
2017-01-26 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
|
EP3573952B1
(en)
|
2017-01-26 |
2021-07-14 |
Boehringer Ingelheim International GmbH |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
|
CN110248929B
(zh)
|
2017-01-26 |
2023-05-12 |
勃林格殷格翰国际有限公司 |
苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
|
US10550127B1
(en)
|
2017-02-08 |
2020-02-04 |
Boehringer Ingelheim International Gmbh |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
WO2018167147A1
(en)
|
2017-03-15 |
2018-09-20 |
F. Hoffmann-La Roche Ag |
Azaindoles as inhibitors of hpk1
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
EP3601258B1
(en)
|
2017-03-27 |
2023-08-30 |
Bristol-Myers Squibb Company |
Substituted isoquionline derivatives as immunomudulators
|
KR20190136028A
(ko)
|
2017-03-30 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
Hpk1 억제제로서의 나프티리딘
|
JP7129420B6
(ja)
|
2017-03-30 |
2024-02-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hpk1阻害剤としてのイソキノリン
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
CA3058578A1
(en)
|
2017-03-31 |
2018-10-04 |
Takeda Pharmaceutical Company Limited |
Aromatic compound
|
JOP20180040A1
(ar)
*
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
WO2018196768A1
(zh)
|
2017-04-26 |
2018-11-01 |
南京圣和药业股份有限公司 |
作为pd-l1抑制剂的杂环类化合物
|
WO2019008156A1
(en)
|
2017-07-07 |
2019-01-10 |
Rijksuniversiteit Groningen |
INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
|
KR102647257B1
(ko)
|
2017-07-28 |
2024-03-13 |
케모센트릭스, 인크. |
면역조절제 화합물
|
US10392405B2
(en)
|
2017-08-08 |
2019-08-27 |
Chemocentryx, Inc. |
Macrocyclic immunomodulators
|
CN111386116B
(zh)
|
2017-08-18 |
2022-06-14 |
上海轶诺药业有限公司 |
一种具有pd-l1抑制活性的化合物、其制备方法及用途
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
EP3692053A1
(en)
|
2017-10-03 |
2020-08-12 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2019074241A1
(ko)
|
2017-10-11 |
2019-04-18 |
정원혁 |
페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
|
CN109678796B
(zh)
|
2017-10-19 |
2023-01-10 |
上海长森药业有限公司 |
Pd-1/pd-l1小分子抑制剂及其制备方法和用途
|
AU2018398887B2
(en)
|
2017-12-29 |
2024-03-14 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd |
Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
|
TWI796596B
(zh)
|
2018-02-13 |
2023-03-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
WO2019165043A2
(en)
|
2018-02-22 |
2019-08-29 |
Chemocentryx, Inc. |
Indane-amines as pd-l1 antagonists
|
SG11202008950PA
(en)
|
2018-03-13 |
2020-10-29 |
Jubilant Prodel LLC |
Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
|
CN111788193B
(zh)
|
2018-03-13 |
2023-04-04 |
广东东阳光药业有限公司 |
Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
|
HRP20230090T1
(hr)
|
2018-03-30 |
2023-03-17 |
Incyte Corporation |
Heterociklički spojevi kao imunomodulatori
|
JP7242702B2
(ja)
|
2018-04-19 |
2023-03-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
CN112752756A
(zh)
|
2018-05-11 |
2021-05-04 |
因赛特公司 |
作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
|
WO2020011246A1
(zh)
|
2018-07-13 |
2020-01-16 |
广州丹康医药生物有限公司 |
含苯环的化合物、其制备方法及应用
|
EP4234030A3
(en)
|
2018-07-13 |
2023-10-18 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|